Despite heavy generic competition, antibiotic hospital market continues to provide commercial opportunities for novel therapies, especially for agents with activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Gram-negative pathogens. Earning a favorable status on the hospital formulary is imperative for emerging therapies vying to gain access to the hospital market.
This study provides an in-depth view of the hospital formulary decision-making process for antibacterial therapies in the United States. Through primary market research with hospital pharmacy directors and infectious diseases specialists who serve on their hospitals’ pharmacy and thera-peutics (P&T) committees, we are able to understand the influence of cost factors, clinical factors, and product attributes on antibiotic formulary deci-sions. The study also provides proprietary historical data on hospital for-mulary inclusion for current therapies, as well as an analysis of anticipat-ed inclusion of emerging antibiotics by P&T committee members.
Questions Answered in This Report:
What is the overall structure of the P&T committees? Who are the key stakeholders and influencers for sales force targeting?
What factors influence formulary decision-making? What is the rela-tive importance of drug-specific attributes and pharmacoeconomic data in driving or constraining formulary inclusion?
What are clinical and administrative challenges for formulary approval of new products?
Are there any ongoing or planned changes to the current hospital formulary?
How has formulary status of key agents evolved in the last ten years? How successfully have recently-launched Teflaro and Dificid penetrat-ed hospital formularies?
What is the current formulary, stocking and restriction status of all currently marketed antibacterial brands?
How will P&T committees evaluate emerging therapies and what is the anticipated formulary status of novel agents?
Which key sales force and drug manufacturer/marketer messages resonate with the P&T committee?
Sample Frame & Methodology:
- ~100 hospital-based infectious diseases (ID) specialists and pharmacy directors complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
To qualify, respodents must meet the following criteria:
- Active and current member of their hospital P&T committee
- Have been in practice a minimum of 2 years and a maximum of 30 years
- More than 50 percent of professional time spent in clinical practice in the hospital setting
- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics and standard cross tabulations
Key Drugs Covered:
- Doribax (doripenem), Invanz(ertapenem), Teflaro (ceftaroline), Zyvox (linezolid), Cubicin (daptomycin), Vibativ (telavancin), Tygacil (tigecycline), Dificid (fidaxomicin), key generic competi-tion, and emerging therapies in late-stage development, including tedizolid, CXA-201, and CAZ-AVI
- Publish: September 2013
Research with Physicians and Pharmacy Directors:
- 100 hospital-based infectious diseases specialists and hospital pharmacy directors who currently sit on their hospital P&T committee
- United States
Key Companies Mentioned:
- Forest Laboratories
- Trius Therapeutics
- Primary market research with hospital P&T committees
- Current formulary status and key restrictions for antibiotics
- Ten years of historical formulary data from AMR’s proprietary hospital formulary database
- Historical drug stocking data
- Influence of cost assessments on formulary decisions
- Process for formulary uptake
- Unmet needs and product differentiation
- Emerging therapies
- Strategic, actionable recom-mendations for optimizing market access
- Hospital Formulary Insights®: Antibiotics (EU)
- TreatmentTrends®: Gram Negative Infections (US)
- TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US)
- TreatmentTrends®: Clostridium Difficile Infections (EU)
- DecisionBase®: Hospital-Acquired Pneumonia
- DecisionBase®: Clostridium Difficile Infections
- PatientBase®: Hospital-Treated Infections in the G7
- Pharmacor®: Hospital-Treated Infections
- Pharmacor®: MRSA Infections
- Physician And Payer Forum®: Gram-Negative Infections (US)
- Physician And Payer Forum®: Outpatient Parenteral Antimicrobial Thera-py (OPAT) for Skin Infections and Osteomyelitis (US)